Families are an important site for the spread of influenza viruses.
Because it can reduce the transmission of the virus, zanamivir shows promise as a way to curb this common domestic problem. The double blind, placebo-controlled clinical trial was designed to examine the effectiveness of Relenza in preventing the spread of influenza A and B from one infected family member to other members. The age range of study participants was 5 to 72. Parents tell us that the spread of influenza among family members is a frequent problem. Annual influenza vaccination is the primary means of influenza protection.